184 related articles for article (PubMed ID: 29192558)
21. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
22. From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Lorenz J; Waldschmidt J; Wider D; Follo M; Ihorst G; Chatterjee M; May AM; Duyster J; Rosenwald A; Wäsch R; Zirlik K; Engelhardt M
Br J Haematol; 2016 Sep; 174(6):985-9. PubMed ID: 26491948
[No Abstract] [Full Text] [Related]
23. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
24. Fostamatinib combined with TPO-RAs or steroids as a bridge to monotherapy or as time-limited continuous treatment in relapsed chronic ITP: A single-centre case series.
Passucci M; Laganà A; Donzelli L; Masucci C; Genoese A; Chistolini A; Baldacci E; Santoro C
Br J Haematol; 2024 May; 204(5):2129-2132. PubMed ID: 38563350
[No Abstract] [Full Text] [Related]
25. Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
McAdoo S; Tam FWK
Semin Nephrol; 2018 Sep; 38(5):496-503. PubMed ID: 30177021
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.
Bukong TN; Iracheta-Vellve A; Saha B; Ambade A; Satishchandran A; Gyongyosi B; Lowe P; Catalano D; Kodys K; Szabo G
Hepatology; 2016 Oct; 64(4):1057-71. PubMed ID: 27302565
[TBL] [Abstract][Full Text] [Related]
27. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
28. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy.
Kapur R
Br J Haematol; 2020 Sep; 190(6):817-818. PubMed ID: 32656765
[No Abstract] [Full Text] [Related]
29. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
30. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
31. Fostamatinib (Tavalisse) for ITP.
Med Lett Drugs Ther; 2019 Feb; 61(1566):28-30. PubMed ID: 30845102
[No Abstract] [Full Text] [Related]
32. Current and emerging treatments based on novel mechanisms for immune thrombocytopenia.
Zeng Q; Zhang X
Sci China Life Sci; 2020 Oct; 63(10):1597-1599. PubMed ID: 32789725
[No Abstract] [Full Text] [Related]
33. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
34. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management.
Provan D; Thachil J; Álvarez Román MT
Expert Rev Hematol; 2024; 17(1-3):55-66. PubMed ID: 38369947
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
36. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
37. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
38. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
39. [Recent topics in the pathophysiology and treatment of immune thrombocytopenic purpura].
Kashiwagi H
Rinsho Ketsueki; 2023; 64(5):397-405. PubMed ID: 37271531
[TBL] [Abstract][Full Text] [Related]
40. Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression.
Lindau A; Härdtner C; Hergeth SP; Blanz KD; Dufner B; Hoppe N; Anto-Michel N; Kornemann J; Zou J; Gerhardt LM; Heidt T; Willecke F; Geis S; Stachon P; Wolf D; Libby P; Swirski FK; Robbins CS; McPheat W; Hawley S; Braddock M; Gilsbach R; Hein L; von zur Mühlen C; Bode C; Zirlik A; Hilgendorf I
Basic Res Cardiol; 2016 Mar; 111(2):20. PubMed ID: 26891724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
